Skip to main content
Premium Trial:

Request an Annual Quote

Bucher Named Associate Director of NTP, Groen Tapped as Agendia COO, Nielson Named Decode COO, and Others

John Bucher has been named associate director of the National Toxicology Program at the National Institute of Environmental Health Sciences. Bucher, who began working with NTP as a toxicologist 24 years ago, will manage day-to-day operations at the NTP.

Agendia has named Jan Groen to the post of chief operating officer. Groen previously was VP of research and development at Focus Diagnostics, and he was co-founder and R&D director at ViroClinics. Groen also was a virologist at the Erasmus Medical Center in Rotterdam and had worked at the management level at the National Institute of Public Health and Environmental Protection in the Netherlands.

Research Corporation Technologies has hired David Bramhill to direct the company’s gene-expression technology program. Before taking the RCT job, Bramhill was founder of Bramhill Biological Consulting, and he worked in research and licensing positions at Merck Research Laboratories.

Decode Genetics has appointed Axel Nielson to be chief operating officer until the company’s next annual meeting of its board of directors, the company stated in an SEC filing this week. Nielson has worked in several positions at Decode, including CFO, VP of finance, treasurer, VP of investor relations, COO of US operations, and VP of operations.

Cequent Pharmaceuticals said this week it has appointed Johannes Fruehauf to be director of pre-clinical and clinical development, and has named Jens Harborth associate director of RNAi research.
Fruehauf previously was manager of lab operations at the GI Cancer lab at Beth Israel Deaconness Medical Center.
Harborth was a senior scientist at Alnylam Pharmaceuticals, where he was developing RNAi-based therapeutics.

SeiraD has named John Talalas to the post of VP of business development. Talalas recently was senior VP of sales and marketing for Cambridge Healthtech Associates. SeiraD said he will initially work on marketing the company’s proteomics and gene-expression data-analysis platform.

WaferGen Bio-systems has appointed Joel Kanter and R. Dean Hautamaki to the company’s board of directors and has named Eugene Bauer to be chairman of its scientific advisory board.
Kanter was president of the private investment company Windy City, was CEO and president of Walnut Financial Services, and he is a board director at Aquamatrix, Echo Healthcare Acquisition, Modigene, I-Flow, and Magna-Lab.
R. Dean Hautamaki is an internist and pulmonary care specialist, and is an assistant clinical professor of medicine at Florida State University. He also formerly was director of Critical Care Medicine and chairman of Medicine at Sarasota Memorial Hospital.
Eugene Bauer was VP of medical affairs at Stanford University, was dean of Stanford’s School of Medicine and was chair of the school’s Department of Dermatology. He is a co-founder of Connetics, and is a member of the board at Protalex, Echo Healthcare Acquisition, Modigene, and Peplin.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.